NCT02724618

Nanocurcumin for Prostate Cancer Patients Undergoing Radiotherapy (RT)

Phase II Study of Nanocurcumin Versus Placebo for Patients Undergoing Radiotherapy for Prostate Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 64 (actual)
• Sponsor: Shahid Beheshti University of Medical Sciences · Academic / Other
• Sex: Male
• Age: —
• Healthy volunteers: Not accepted

Summary

There is a growing body of evidence exploring the role of curcumin as a radioprotector against radiation-induced injury in normal tissues as well as a radiosensitizer in tumor cells. The aim of this study is to determine the efficacy of oral nanocurcumin in prostate cancer patients undergoing radiotherapy.

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Curcumin	120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
RADIATION	RT	EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
DRUG	Placebo	Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy

Timeline

• Start date: 2016-03-01
• Primary completion: 2017-04-15
• Completion: 2022-04-01
• First posted: 2016-03-31
• Last updated: 2017-10-12

Locations

1 site across 1 country: Iran